Patents by Inventor Randall Bateman

Randall Bateman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
    Patent number: 12493043
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: December 9, 2025
    Assignee: Washington University
    Inventors: Randall Bateman, Nicolas Barthelemy
  • METHODS TO DETECT AB PROTEOFORMS AND USE THEREOF
    Publication number: 20250306037
    Abstract: The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Application
    Filed: May 11, 2023
    Publication date: October 2, 2025
    Inventors: Kwasi MAWUENYEGA, Randall BATEMAN
  • METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER'S DISEASE, AND USE THEREOF
    Publication number: 20250147049
    Abstract: The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 8, 2025
    Inventors: Randall Bateman, Eric McDade, Nicolas Barthelemy, Kanta Horie, Yan Li
  • METHODS OF USING AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY AND ANTI-TAU ANTIBODY
    Publication number: 20250051427
    Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-A? protofibril antibody and anti-tau antibody.
    Type: Application
    Filed: November 8, 2022
    Publication date: February 13, 2025
    Inventors: Larisa REYDERMAN, Jin ZHOU, Lynn KRAMER, Michael IRIZARRY, Pallavi SACHDEV, Shobha DHADDA, David LI, Kristin WILDSMITH, Pau ACEVES BALDO, Sumit RAWAL, Akihiko KOYAMA, Chad SWANSON, Michio KANEKIYO, June KAPLOW, David VERBEL, Ishani LANDRY, Seiichi HAYATO, Robert GORDON, Randall BATEMAN, Eric MCDADE
  • METHODS FOR DETECTING NEUROFILAMENT LIGHT CHAIN IN PLASMA AND CEREBROSPINAL FLUID
    Publication number: 20250020669
    Abstract: The present disclosure provides methods to detect and optionally quantify Nfl present in cerebrospinal fluid and blood and use of the methods to detect and optionally measure levels of Nfl biomarkers indicative of neuronal damage. Also disclosed are anti-Nfl antibodies.
    Type: Application
    Filed: February 10, 2022
    Publication date: January 16, 2025
    Inventors: Randall Bateman, Melissa Budelier, David Holtzman, Hong Jiang
  • Blood-based methods for determining A? amyloidosis
    Patent number: 12066444
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: August 20, 2024
    Assignee: Washington University
    Inventor: Randall Bateman
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20230341421
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 26, 2023
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • CSF PHOSPHORYLATED TAU AND AMYLOID BETA PROFILES AS BIOMARKERS OF TAUOPATHIES
    Publication number: 20230280357
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues and optionally Ab species to diagnose a subject, guide treatment decisions, and select subjects for clinical trials.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 7, 2023
    Inventors: CHIHIRO SATO, NICOLAS BARTHELEMY, RANDALL BATEMAN
  • Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease
    Publication number: 20230132508
    Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 4, 2023
    Applicants: Genentech Inc., Washington University
    Inventors: Kristin Ruth Wildsmith, Balazs Toth, Randall Bateman, Nicolas Barthelemy
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11635440
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 25, 2023
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • BLOOD-BASED ASSAY FOR DIAGNOSING AND TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20230017557
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: September 10, 2020
    Publication date: January 19, 2023
    Inventors: RANDALL BATEMAN, NICOLAS BARTHELEMY
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20220317136
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 6, 2022
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF
    Publication number: 20220299527
    Abstract: The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R-tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 22, 2022
    Inventors: RANDALL BATEMAN, CHIHIRO SATO, KANTA HORIE, NICOLAS BARTHELEMY
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11402392
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 2, 2022
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • MULTIPLEXED ASSAY AND METHODS OF USE THEREOF
    Publication number: 20220120765
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 21, 2022
    Inventors: Melissa Budelier, Randall Bateman
  • METHODS FOR TREATING TAUOPATHIES
    Publication number: 20220064271
    Abstract: This invention relates to epitope binding agents that specifically bind to tau and methods of use thereof. The disclosure provides immunoassays, kits, and pharmaceutical compositions which include an epitope binding agent that specifically bind to tau. The disclosure provides methods of reducing the spread of tau aggregates and methods of reducing a tauopathy-related pathology.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Inventors: Randall Bateman, David Holtzman, Kanta Horie, Nicolas Barthelemy, Chihiro Sato, Hong Jiang
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20210341495
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 4, 2021
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • BLOOD-BASED METHODS FOR DETERMING A-BETA AMYLOIDOSIS
    Publication number: 20210255201
    Abstract: The present disclosure provides methods for blood-based examination useful to identify subjects with A? amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for A? amyloidosis, as well as methods for treating subjects diagnosed with A? amyloidosis by the methods disclosed herein.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 19, 2021
    Inventor: Randall Bateman
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11085935
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • TAU KINETIC MEASUREMENTS
    Publication number: 20210096139
    Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 1, 2021
    Inventors: Randall Bateman, Chihiro Sato, Kwasi Mawuenyega, Tim Miller, David Holtzman